Safety and Immunogenicity of Vaccination With MART-1 (26-35, 27 L), gp100 (209-217, 210 M), and Tyrosinase (368-376, 370D) in Adjuvant With PF-3512676 and GM-CSF in Metastatic Melanoma: ErratumJournal of Immunotherapy: October 2012 - Volume 35 - Issue 8 - p 650 doi: 10.1097/CJI.0b013e318271fa57 Erratum Article Outline REFERENCE The article by Tarhini et al,1 appearing on page 359 of the May 2012 issue of the Journal of Immunotherapy, published with an incomplete Acknowledgments section. The complete paragraph appears below and the online version of the article has been corrected. “The project described was supported by Award Number P50CA121973 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.”Back to Top | Article Outline REFERENCE1. Tarhini AA, Leng S, Moschos SJ, et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27 l), gp100 (209-217, 210 M), and tyrosinase (368-376, 370D) in adjuvant with pf-3512676 and GM-CSF in metastatic melanoma. J Immunotherapy. 2012;35:359–366 Cited Here... © 2012 Lippincott Williams & Wilkins, Inc.